Pennsylvania 2023-2024 Regular Session

Pennsylvania Senate Bill SB741

Introduced
6/14/23  

Caption

Providing for disclosures for certain products.

Impact

The implications of SB741 are significant, as it establishes a framework for accountability among manufacturers of health products. By mandating conspicuous labeling, the bill seeks to protect consumers by providing them with crucial information before they engage with products that might carry health risks. This could lead to a more informed public as individuals will be better equipped to make decisions about the medical interventions and products they choose to use, thereby enhancing public health outcomes.

Summary

Senate Bill 741 (SB741) was introduced in Pennsylvania with the primary aim of enhancing transparency regarding various health-related products, particularly gene therapy products. The bill amends Title 35 of the Pennsylvania Consolidated Statutes and establishes specific labeling requirements for products classified as gene therapy or that might pertain to genetic alterations. Under the proposed legislation, any product that could potentially impact genetic makeup or expose individuals to diseases must be clearly labeled, thus ensuring consumers are aware of the nature and implications of such products before use.

Sentiment

The sentiment surrounding SB741 appears to be largely supportive among proponents who emphasize the necessity of informed consent and transparency in health products. Advocates argue that the bill is a step towards empowering consumers. Conversely, there may be some contention from industry representatives who might see the new requirements as burdensome or potentially detrimental to innovation in the health sector. The discussions suggest there is a balance that needs to be struck between regulation and industry freedom.

Contention

Notable points of contention relate to the extent of the regulatory requirements imposed on manufacturers. Critics worry that stringent labeling and documentation demands could stifle innovation by creating barriers to market entry for new health products. Additionally, there are concerns regarding how compliance will be monitored and enforced, thus leading to debates about the practicality and enforceability of the proposed legislation.

Companion Bills

No companion bills found.

Previously Filed As

PA SB883

Providing for prohibition of and disclosures for certain products.

PA SB1186

Requires disclosure for certain products produced, sold, or distributed in Missouri

PA SB252

Requires disclosure for certain products produced, sold, or distributed in Missouri

PA HB216

Gene Therapy Product Disclosure

PA HB812

Establishing the Protecting Hospital Workers from Workplace Violence Grant Program and the Protecting Hospital Workers from Workplace Violence Grant Fund; providing for duties of Department of Health; and making a transfer.

PA HB829

Requires disclosure and labeling on all food products derived from genetically engineered agricultural products

PA HB229

AN ACT relating to gene therapy.

PA H3096

Gene Therapy

PA SB885

In public safety, establishing the Reproductive Health Services Address Confidentiality Program; and imposing penalties.

PA HB1443

Establishing the Statewide Advisory Council on Playground Safety; and providing for duties of the Statewide Advisory Council on Playground Safety.

Similar Bills

CA SB277

Criminal procedure: search of persons.

CA AB937

Plastic products: commercial agricultural mulch film: labeling: soil biodegradable.

CA AB2632

Segregated confinement.

CA AB1464

Housing preferences.

MI SB0975

Employment security: benefits; disqualification from benefits; modify. Amends sec. 29 of 1936 (Ex Sess) PA 1 (MCL 421.29).

CA AB2564

Individual Shared Responsibility Penalty: waiver: health care service plans.

CA SB479

Termination of tenancy: no-fault just cause: natural person.

CA SB1428

Reproductive health: mifepristone and other medication.